QQQ   359.75 (+1.36%)
AAPL   173.66 (+0.73%)
MSFT   318.96 (+1.77%)
META   305.58 (+1.54%)
GOOGL   135.24 (+2.12%)
AMZN   127.00 (+1.83%)
TSLA   261.16 (+5.93%)
NVDA   440.41 (+1.20%)
NIO   8.83 (+2.56%)
BABA   84.05 (-0.58%)
AMD   104.07 (+3.99%)
T   14.65 (-0.88%)
F   11.98 (-0.75%)
MU   68.11 (+0.41%)
CGC   0.75 (+10.25%)
GE   108.85 (+1.01%)
DIS   79.30 (-0.30%)
AMC   8.34 (+6.24%)
PFE   33.29 (-1.80%)
PYPL   58.57 (+2.22%)
NFLX   376.90 (+0.04%)
QQQ   359.75 (+1.36%)
AAPL   173.66 (+0.73%)
MSFT   318.96 (+1.77%)
META   305.58 (+1.54%)
GOOGL   135.24 (+2.12%)
AMZN   127.00 (+1.83%)
TSLA   261.16 (+5.93%)
NVDA   440.41 (+1.20%)
NIO   8.83 (+2.56%)
BABA   84.05 (-0.58%)
AMD   104.07 (+3.99%)
T   14.65 (-0.88%)
F   11.98 (-0.75%)
MU   68.11 (+0.41%)
CGC   0.75 (+10.25%)
GE   108.85 (+1.01%)
DIS   79.30 (-0.30%)
AMC   8.34 (+6.24%)
PFE   33.29 (-1.80%)
PYPL   58.57 (+2.22%)
NFLX   376.90 (+0.04%)
QQQ   359.75 (+1.36%)
AAPL   173.66 (+0.73%)
MSFT   318.96 (+1.77%)
META   305.58 (+1.54%)
GOOGL   135.24 (+2.12%)
AMZN   127.00 (+1.83%)
TSLA   261.16 (+5.93%)
NVDA   440.41 (+1.20%)
NIO   8.83 (+2.56%)
BABA   84.05 (-0.58%)
AMD   104.07 (+3.99%)
T   14.65 (-0.88%)
F   11.98 (-0.75%)
MU   68.11 (+0.41%)
CGC   0.75 (+10.25%)
GE   108.85 (+1.01%)
DIS   79.30 (-0.30%)
AMC   8.34 (+6.24%)
PFE   33.29 (-1.80%)
PYPL   58.57 (+2.22%)
NFLX   376.90 (+0.04%)
QQQ   359.75 (+1.36%)
AAPL   173.66 (+0.73%)
MSFT   318.96 (+1.77%)
META   305.58 (+1.54%)
GOOGL   135.24 (+2.12%)
AMZN   127.00 (+1.83%)
TSLA   261.16 (+5.93%)
NVDA   440.41 (+1.20%)
NIO   8.83 (+2.56%)
BABA   84.05 (-0.58%)
AMD   104.07 (+3.99%)
T   14.65 (-0.88%)
F   11.98 (-0.75%)
MU   68.11 (+0.41%)
CGC   0.75 (+10.25%)
GE   108.85 (+1.01%)
DIS   79.30 (-0.30%)
AMC   8.34 (+6.24%)
PFE   33.29 (-1.80%)
PYPL   58.57 (+2.22%)
NFLX   376.90 (+0.04%)
NASDAQ:IMPL

Impel Pharmaceuticals (IMPL) Stock Forecast, Price & News

$0.41
0.00 (0.00%)
(As of 10/4/2023 ET)
Compare
Today's Range
$0.41
$0.44
50-Day Range
$0.31
$1.49
52-Week Range
$0.29
$5.34
Volume
50,374 shs
Average Volume
546,023 shs
Market Capitalization
$9.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.67

Impel Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
4,685.1% Upside
$19.67 Price Target
Short Interest
Bearish
23.77% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.40) to ($1.10) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.82 out of 5 stars

Medical Sector

776th out of 966 stocks

Pharmaceutical Preparations Industry

360th out of 443 stocks


IMPL stock logo

About Impel Pharmaceuticals (NASDAQ:IMPL) Stock

Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. The company was incorporated in 2008 and is headquartered in Seattle, Washington.

IMPL Price History

IMPL Stock News Headlines

Impel Pharmaceuticals (IMPL) Receives a Hold from JonesTrading
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Biotech Catches Major Premarket Bid
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
84P.SG - Impel Pharmaceuticals Inc
Impel Pharmaceuticals Inc. (IMPL)
Impel Pharmaceuticals gets new CFO
See More Headlines
Receive IMPL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Impel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

IMPL Company Calendar

Last Earnings
8/18/2023
Today
10/04/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IMPL
Fax
N/A
Employees
160
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$19.67
High Stock Price Forecast
$40.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+4,695.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-106,310,000.00
Net Margins
-480.74%
Pretax Margin
-480.74%

Debt

Sales & Book Value

Annual Sales
$12.65 million
Book Value
($1.86) per share

Miscellaneous

Free Float
22,277,000
Market Cap
$9.74 million
Optionable
Not Optionable
Beta
0.06
10 Best Stocks to Own in 2023 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Adrian AdamsMr. Adrian Adams (Age 72)
    Chairman, CEO & Pres
    Comp: $829.17k
  • Mr. Leonard S. Paolillo (Age 44)
    Chief Commercial Officer
    Comp: $523.97k
  • Dr. John D. Hoekman Ph.D. (Age 42)
    Co-Founder and Chief Technology & Devel. Officer
  • Mr. Michael W. Kalb CPA (Age 52)
    Chief Financial Officer
  • Ms. Jennifer L. Berman
    VP of Marketing
  • Ms. Patty Billingsley
    VP of Sales
  • Ms. Sarah Wille
    VP of HR
  • Dr. Lynn C. Gold Ph.D. (Age 66)
    Sr. VP of Regulatory
  • Mr. Scott Youmans (Age 56)
    Sr. VP of Technical Operations
  • Mr. Rajiv Amin (Age 47)
    VP, Controller & Corp. Sec.













IMPL Stock - Frequently Asked Questions

Should I buy or sell Impel Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Impel Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" IMPL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IMPL, but not buy additional shares or sell existing shares.
View IMPL analyst ratings
or view top-rated stocks.

What is Impel Pharmaceuticals' stock price forecast for 2023?

1 brokerages have issued 1-year price objectives for Impel Pharmaceuticals' shares. Their IMPL share price forecasts range from $5.00 to $40.00. On average, they expect the company's stock price to reach $19.67 in the next twelve months. This suggests a possible upside of 4,695.6% from the stock's current price.
View analysts price targets for IMPL
or view top-rated stocks among Wall Street analysts.

How have IMPL shares performed in 2023?

Impel Pharmaceuticals' stock was trading at $3.75 at the start of the year. Since then, IMPL stock has decreased by 89.1% and is now trading at $0.4101.
View the best growth stocks for 2023 here
.

Are investors shorting Impel Pharmaceuticals?

Impel Pharmaceuticals saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 1,840,000 shares, an increase of 264.3% from the August 31st total of 505,100 shares. Based on an average daily trading volume, of 1,490,000 shares, the short-interest ratio is presently 1.2 days. Currently, 23.8% of the company's shares are sold short.
View Impel Pharmaceuticals' Short Interest
.

When is Impel Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our IMPL earnings forecast
.

How were Impel Pharmaceuticals' earnings last quarter?

Impel Pharmaceuticals Inc. (NASDAQ:IMPL) posted its quarterly earnings data on Friday, August, 18th. The company reported ($0.31) earnings per share for the quarter. The business earned $6.58 million during the quarter.

When did Impel Pharmaceuticals IPO?

(IMPL) raised $80 million in an initial public offering on Friday, April 23rd 2021. The company issued 5,300,000 shares at $14.00-$16.00 per share. Cowen, Guggenheim Securities and Wedbush PacGrow served as the underwriters for the IPO.

What is Impel Pharmaceuticals' stock symbol?

Impel Pharmaceuticals trades on the NASDAQ under the ticker symbol "IMPL."

How do I buy shares of Impel Pharmaceuticals?

Shares of IMPL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Impel Pharmaceuticals' stock price today?

One share of IMPL stock can currently be purchased for approximately $0.41.

How much money does Impel Pharmaceuticals make?

Impel Pharmaceuticals (NASDAQ:IMPL) has a market capitalization of $9.74 million and generates $12.65 million in revenue each year. The company earns $-106,310,000.00 in net income (profit) each year or ($3.86) on an earnings per share basis.

How many employees does Impel Pharmaceuticals have?

The company employs 160 workers across the globe.

How can I contact Impel Pharmaceuticals?

The official website for the company is www.Impelnp.com. The company can be reached via phone at 206-568-1466.

This page (NASDAQ:IMPL) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -